Quantum Biopharma Ltd (QNTM)

$3.83 -0.52 (-11.95%)
Market Cap 16.60M
Revenue (ttm) 0.00
Net Income (ttm) -14.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 281,000
Avg Vol 258,984
Day's Range N/A - N/A
Shares Out 3.82M
Stochastic %K 48%
Beta 0.32
Analysts Sell
Price Target $35.50

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is...

Industry: Biotechnology
Sector: Healthcare
Phone: 833 571 1811
Address:
55 University Avenue, Suite 1003, Toronto, Canada
Stackdoe101
Stackdoe101 Mar. 26 at 6:48 PM
$OPTX $QNTM $AIFF 🙃✨️
0 · Reply
mohamettarik
mohamettarik Mar. 26 at 5:18 PM
$QNTM i raised hand 🙋 two days consistently ….
0 · Reply
gloryb
gloryb Mar. 26 at 4:06 PM
$QNTM fucking scumbags
0 · Reply
Stackdoe101
Stackdoe101 Mar. 26 at 2:34 PM
$QNTM 🤩
0 · Reply
RamenSoups
RamenSoups Mar. 26 at 2:06 PM
$QNTM $GNS lol
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 26 at 2:05 PM
$QNTM gonna test 3.14 the next support ..=sell
0 · Reply
Tumbleweedloseshismoney
Tumbleweedloseshismoney Mar. 26 at 2:04 PM
$QNTM dead money
0 · Reply
ZacksResearch
ZacksResearch Mar. 26 at 1:28 PM
$QNTM gearing up for a key clinical milestone — is this the real inflection point? The company just appointed a top-tier MS expert as Principal Investigator for its planned Phase 2 trial of Lucid-MS, while preparing to submit an IND to the FDA in the coming weeks — a critical step toward clinical validation. 🧬 Lucid-MS is a first-in-class, neuroprotective compound targeting demyelination, a major unmet need in Multiple Sclerosis. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37536&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37536
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 26 at 12:18 PM
$QNTM boom 4.40 lol
0 · Reply
DARKP00L
DARKP00L Mar. 26 at 12:07 PM
$QNTM 08:02 on Mar. 26 2026 Quantum Biopharma Appoints Dr. Salvatore Napoli As Principal Investigator For Phase 2 Clinical Trial Of Lucid-21-302 For Treatment Of Demyelination In Multiple Sclerosis #tradeideas
0 · Reply
Latest News on QNTM
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Mon, 23 Mar 2026 08:24:00 -0400 - 3 days ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Fri, 20 Mar 2026 19:35:00 -0400 - 6 days ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Quantum BioPharma Provides Corporate Update

Wed, 11 Mar 2026 19:55:00 -0400 - 15 days ago

Quantum BioPharma Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 19:29:00 -0500 - 5 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Thu, 19 Feb 2026 12:00:00 -0500 - 5 weeks ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 13:55:00 -0500 - 5 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 12:59:00 -0500 - 5 weeks ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Tue, 17 Feb 2026 09:41:00 -0500 - 5 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 12 Feb 2026 16:02:00 -0500 - 6 weeks ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 7 weeks ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Mon, 02 Feb 2026 10:46:00 -0500 - 7 weeks ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 27 Jan 2026 13:42:00 -0500 - 2 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Dec 23, 2025, 8:00 AM EST - 3 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Mon, 22 Dec 2025 09:00:00 -0500 - 3 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Dec 10, 2025, 8:00 PM EST - 3 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 27, 2025, 4:00 PM EST - 4 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Nov 26, 2025, 9:30 AM EST - 4 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Nov 7, 2025, 7:00 AM EST - 4 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Quantum BioPharma Ltd. Provides Corporate Update

Oct 31, 2025, 7:51 PM EDT - 5 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 29, 2025, 9:00 PM EDT - 5 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

Oct 23, 2025, 8:15 AM EDT - 5 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 20, 2025, 8:30 AM EDT - 5 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Oct 14, 2025, 8:15 AM EDT - 5 months ago

Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 9, 2025, 6:00 PM EDT - 6 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

Oct 9, 2025, 5:40 PM EDT - 6 months ago

QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 8, 2025, 8:00 AM EDT - 6 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 7, 2025, 11:00 AM EDT - 6 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 3, 2025, 7:00 AM EDT - 6 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 2, 2025, 7:57 AM EDT - 6 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Oct 1, 2025, 7:50 AM EDT - 6 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 29, 2025, 7:40 AM EDT - 6 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Quantum BioPharma Announces Corporate Updates

Sep 26, 2025, 8:00 PM EDT - 6 months ago

Quantum BioPharma Announces Corporate Updates

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 24, 2025, 8:30 AM EDT - 6 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 18, 2025, 8:10 AM EDT - 6 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 12, 2025, 7:50 AM EDT - 6 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Sep 10, 2025, 7:00 AM EDT - 7 months ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 6:32 PM EDT - 8 months ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 11, 2025, 7:40 AM EDT - 8 months ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 8, 2025, 8:00 AM EDT - 8 months ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 7, 2025, 7:00 AM EDT - 8 months ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 5, 2025, 7:34 AM EDT - 8 months ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Aug 4, 2025, 7:33 AM EDT - 8 months ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Jul 31, 2025, 7:24 AM EDT - 8 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Jul 30, 2025, 4:00 PM EDT - 8 months ago

Quantum BioPharma Shares' Rollercoaster Day: What's Going On?

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

Jul 22, 2025, 7:00 AM EDT - 8 months ago

Quantum BioPharma Makes Strategic Investment in GameStop Corp.

GME

Quantum BioPharma Announces Private Placement

Jun 27, 2025, 4:30 PM EDT - 9 months ago

Quantum BioPharma Announces Private Placement

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Jun 26, 2025, 7:30 AM EDT - 9 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Jun 18, 2025, 9:19 AM EDT - 10 months ago

Singular Research Reports on Quantum BioPharma Ltd.'s Strategic Advances and Pipeline Progress

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Jun 17, 2025, 8:00 AM EDT - 10 months ago

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Jun 13, 2025, 7:00 AM EDT - 10 months ago

Quantum BioPharma Announces Intention to Declare Special Dividend of Contingent Value Rights (CVRs) Linked to Future Litigation Settlement Proceeds

Quantum BioPharma Clarifies It Has Not Changed Its Name

Jun 3, 2025, 7:50 AM EDT - 10 months ago

Quantum BioPharma Clarifies It Has Not Changed Its Name

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

Jun 2, 2025, 1:47 PM EDT - 10 months ago

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

May 30, 2025, 7:00 AM EDT - 10 months ago

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

May 29, 2025, 7:30 AM EDT - 10 months ago

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

May 28, 2025, 8:00 AM EDT - 10 months ago

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

May 20, 2025, 7:30 AM EDT - 11 months ago

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000

May 19, 2025, 7:30 AM EDT - 11 months ago

Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

May 16, 2025, 7:30 AM EDT - 11 months ago

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

May 12, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

May 5, 2025, 7:08 AM EDT - 11 months ago

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Stackdoe101
Stackdoe101 Mar. 26 at 6:48 PM
$OPTX $QNTM $AIFF 🙃✨️
0 · Reply
mohamettarik
mohamettarik Mar. 26 at 5:18 PM
$QNTM i raised hand 🙋 two days consistently ….
0 · Reply
gloryb
gloryb Mar. 26 at 4:06 PM
$QNTM fucking scumbags
0 · Reply
Stackdoe101
Stackdoe101 Mar. 26 at 2:34 PM
$QNTM 🤩
0 · Reply
RamenSoups
RamenSoups Mar. 26 at 2:06 PM
$QNTM $GNS lol
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 26 at 2:05 PM
$QNTM gonna test 3.14 the next support ..=sell
0 · Reply
Tumbleweedloseshismoney
Tumbleweedloseshismoney Mar. 26 at 2:04 PM
$QNTM dead money
0 · Reply
ZacksResearch
ZacksResearch Mar. 26 at 1:28 PM
$QNTM gearing up for a key clinical milestone — is this the real inflection point? The company just appointed a top-tier MS expert as Principal Investigator for its planned Phase 2 trial of Lucid-MS, while preparing to submit an IND to the FDA in the coming weeks — a critical step toward clinical validation. 🧬 Lucid-MS is a first-in-class, neuroprotective compound targeting demyelination, a major unmet need in Multiple Sclerosis. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37536&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37536
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 26 at 12:18 PM
$QNTM boom 4.40 lol
0 · Reply
DARKP00L
DARKP00L Mar. 26 at 12:07 PM
$QNTM 08:02 on Mar. 26 2026 Quantum Biopharma Appoints Dr. Salvatore Napoli As Principal Investigator For Phase 2 Clinical Trial Of Lucid-21-302 For Treatment Of Demyelination In Multiple Sclerosis #tradeideas
0 · Reply
FickleFin
FickleFin Mar. 26 at 12:03 PM
$QNTM $GNS Remember WHEN the CFO SOLD his shares... here to collect. 🤌
0 · Reply
FickleFin
FickleFin Mar. 26 at 11:59 AM
$QNTM $GNS paid pumpers, articles, bots (example below). Its the same scenario. Rinse and repeat. Hate the players and their game.
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Mar. 26 at 11:56 AM
$QNTM down 10% on 9k shares
0 · Reply
nopennys
nopennys Mar. 26 at 9:06 AM
$GNS $QNTM $CYCU Scam
2 · Reply
FickleFin
FickleFin Mar. 26 at 8:30 AM
$QNTM $GNS idiot investing Once again, management recieves compensation of shares 1 day before the unbuzzd study press release. These guys are literally stealing investor $$$ in front of you and you cheer them on. Structured already where they own majority the share float. 🚩🚩🚩🚩🚩🚩Retail hold 87% of this stock. No institutional $ is here...no revenue.
0 · Reply
StockScanners
StockScanners Mar. 26 at 4:05 AM
$QNTM reached 5.65
0 · Reply
mohamettarik
mohamettarik Mar. 25 at 8:27 PM
$QNTM i am not asking to sell or buy... .do your exercise ... love you money
0 · Reply
mohamettarik
mohamettarik Mar. 25 at 8:25 PM
$QNTM when ?
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 25 at 4:59 PM
$QNTM I'm out..taking my profits ...gl
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 25 at 4:10 PM
$QNTM I 👁👃👁 1 more rally into close to hopefully hit 6.40 resist 😉
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 25 at 2:55 PM
$QNTM SPRTS= 4.20 @ 50 DMAV RSIST= 6.38 @ 100 DMA
0 · Reply
JUST_FACTSSS
JUST_FACTSSS Mar. 25 at 2:18 PM
$QNTM
0 · Reply